New drug treatments for certain types of diseases pancreatic cancer It recently received approval from the U.S. Food and Drug Administration (FDA). This is the first new drug in almost 10 years.
Onivide (irinotecan liposome), an injectable drug manufactured by Ipsen, is approved for use in combination with oxaliplatin, fluorouracil, and leucovorin in a regimen for patients with metastatic pancreatic adenocarcinoma (mPDAC).
According to the National Institutes of Health (NIH), this type of cancer is an aggressive malignancy with a life expectancy of 8 to 11 months.
On this day in history, March 6, 2019, Alex Trebek tells the world about his cancer diagnosis.
This approval is randomized controlled trial That included 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy, according to an FDA press release.
The group of patients who received the new intravenous regimen showed “significant improvements” in survival and response rates compared to the control group.
A new treatment for certain types of pancreatic cancer recently received approval from the U.S. Food and Drug Administration. (St. Petersburg)
Medications are administered by IV for 90 minutes every two weeks.
“We’re hopeful that this regimen will become a new standard, meaning we’ll add to it in the future,” said Dr. Zev Weinberg, professor of medicine and co-director of the UCLA GI Oncology Program in Los Angeles. He told News Digital.
It turns out that AI can predict the risk of pancreatic cancer long before symptoms appear
“Before proceeding, we needed clarity on the data provided by the Phase 3 trial.”
metastatic pancreatic cancer Weinberg noted that it is one of the most difficult cancers to treat because it does not respond well to new drugs that treat other types of diseases.
“Unfortunately, patients are often very ill, and many cancers grow too quickly for drugs to respond to them in the same way as other cancers,” he said.
Metastatic pancreatic cancer is one of the most difficult cancers to treat because it doesn’t respond well to new drugs that are effective against other types of disease, doctors said. (St. Petersburg)
Dr. Mark Siegel, Clinical Professor, School of Medicine New York University Langone Medical Center A Fox News medical contributor said the drug is “a useful new tool, but it’s not a game-changer.”
“It’s effective when combined with other chemotherapy treatments used for a wide range of pancreatic cancers,” Siegel told Fox News Digital.
“It works by interfering with DNA replication within the cancer and damaging DNA repair in the tumor.”
Can a urine test detect pancreatic or prostate cancer? Studies show 99% success rate
Peter Hossain, MD, associate director of clinical research at the Pancreatic Cancer Institute at the University of Miami Sylvester Comprehensive Cancer Center, also commented on the new approval.
“Pancreatic cancer is a deadly disease, and meaningful advances in prevention, early detection, and treatment are desperately needed to improve outcomes,” he told Fox News Digital.
The group of patients who received the new intravenous regimen showed “significant improvements” in survival and response rates compared to the control group. (St. Petersburg)
Onibide is a new formulation of an old drug and is “nearly identical,” Hossain said.
“So while this is a new authorization, it doesn’t really represent meaningful progress,” he told FOX News Digital.
Click here to sign up for our health newsletter
Onivide is also “significantly more expensive” than the existing irinotecan. standard medicineHossein pointed out.
“Many doctors and scientists are working around the clock to study this disease, and survival rates are gradually improving,” he said.
“We need to continue to focus on breakthrough treatments that really move the needle to save patients.”
Regarding pancreatic cancer, one doctor said, “Many doctors and scientists are working around the clock to study this disease, and survival rates are gradually improving.” (St. Petersburg)
The FDA says the most commonly reported side effects of Onivide are diarrhea, nausea, vomiting, fatigue, decreased appetite, abdominal pain, mucosal inflammation, constipation, and weight loss.
“Every drug has a safety profile that needs to be taken seriously,” Weinberg said.
CLICK HERE TO GET THE FOX NEWS APP
“Here, most combinations are generated gastrointestinal upset — Diarrhea and possibly dehydration — Therefore, preventive (preventative) management is important. ”
Fox News Digital has reached out to Ipsen, a French biopharmaceutical company headquartered in Paris, France, for additional comment.
For more health articles, visit: www.foxnews.com/health.
